Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.27 +0.7%	$0.26	$0.20 ▼ $1.48	$71.42M	2.86	1.81 million shs	310,615 shs
CMPX Compass Therapeutics	$2.12 +1.0%	$1.90	$0.77 ▼ $4.08	$293.16M	1.4	922,432 shs	464,494 shs
IMMP Immutep	$1.97 +2.1%	$1.74	$1.32 ▼ $3.05	$287.70M	1.8	201,877 shs	133,702 shs
TRDA Entrada Therapeutics	$7.90 +1.7%	$8.46	$7.10 ▼ $21.79	$299.83M	0.04	130,796 shs	87,408 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	-3.28%	-1.42%	-2.17%	-50.81%	-73.93%
CMPX Compass Therapeutics	-0.47%	+1.94%	+10.53%	-28.08%	+37.25%
IMMP Immutep	-3.02%	-0.52%	+16.97%	+1.58%	-32.28%
TRDA Entrada Therapeutics	+0.91%	+1.04%	-12.40%	-35.14%	-51.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	2.7612 of 5 stars	4.2	3.0	3.2	0.8	0.0
CMPX Compass Therapeutics	4.031 of 5 stars	4.6	3.0	3.4	5.0	0.0
IMMP Immutep	1.2876 of 5 stars	3.5	1.0	2.5	0.0	0.0
TRDA Entrada Therapeutics	2.9474 of 5 stars	3.6	2.0	3.3	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.43	Hold	$1.52	455.96% Upside
CMPX Compass Therapeutics	3.11	Buy	$13.13	519.10% Upside
IMMP Immutep	3.00	Buy	$7.00	255.33% Upside
TRDA Entrada Therapeutics	3.25	Buy	$25.67	224.89% Upside

Current Analyst Ratings Breakdown

Latest ADAP, CMPX, TRDA, and IMMP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/22/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/21/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
4/21/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/11/2025	ADAP Adaptimmune Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/4/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $24.00
4/2/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$179.64M	0.40	N/A	N/A	$0.17 per share	1.61
CMPX Compass Therapeutics	$850K	344.89	N/A	N/A	$1.17 per share	1.81
IMMP Immutep	$5.14M	55.97	N/A	N/A	$1.05 per share	1.88
TRDA Entrada Therapeutics	$172.22M	1.74	N/A	N/A	$7.26 per share	1.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$113.87M	-$0.27	N/A	N/A	N/A	-25.43%	-74.15%	-15.09%	8/11/2025 (Estimated)
CMPX Compass Therapeutics	-$42.49M	-$0.41	N/A	N/A	N/A	N/A	-32.37%	-30.67%	8/11/2025 (Estimated)
IMMP Immutep	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
TRDA Entrada Therapeutics	-$6.68M	$0.81	4.97	N/A	N/A	25.53%	16.11%	10.39%	8/12/2025 (Estimated)

Latest ADAP, CMPX, TRDA, and IMMP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
5/8/2025	Q1 2025	TRDA Entrada Therapeutics	-$0.78	-$0.42	+$0.36	-$0.42	$10.98 million	$8.75 million
3/24/2025	Q4 2024	ADAP Adaptimmune Therapeutics	-$0.17	-$0.26	-$0.09	-$0.29	$16.56 million	$3.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
IMMP Immutep	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	0.62	3.85	3.82
CMPX Compass Therapeutics	N/A	31.84	31.84
IMMP Immutep	0.01	18.25	18.25
TRDA Entrada Therapeutics	N/A	6.59	6.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
CMPX Compass Therapeutics	68.43%
IMMP Immutep	2.32%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.44%
CMPX Compass Therapeutics	29.80%
IMMP Immutep	3.07%
TRDA Entrada Therapeutics	8.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	261.52 million	224.05 million	Optionable
CMPX Compass Therapeutics	20	138.28 million	98.38 million	Not Optionable
IMMP Immutep	2,021	146.04 million	141.09 million	Optionable
TRDA Entrada Therapeutics	110	37.95 million	34.58 million	Optionable

ADAP, CMPX, TRDA, and IMMP Headlines

Recent News About These Companies

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 28 at 7:00 AM | globenewswire.com

Q2 EPS Estimate for Entrada Therapeutics Raised by Analyst

May 24, 2025 | marketbeat.com

HC Wainwright Has Positive Forecast for TRDA Q2 Earnings

May 24, 2025 | americanbankingnews.com

What is HC Wainwright's Estimate for TRDA Q2 Earnings?

May 23, 2025 | marketbeat.com

Northern Trust Corp Has $5.50 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 23, 2025 | marketbeat.com

Q2 Earnings Forecast for TRDA Issued By HC Wainwright

May 23, 2025 | americanbankingnews.com

Entrada Therapeutics' (TRDA) "Buy" Rating Reaffirmed at HC Wainwright

May 23, 2025 | americanbankingnews.com

Entrada Therapeutics (NASDAQ:TRDA) Given "Buy" Rating at HC Wainwright

May 22, 2025 | marketbeat.com

Janus Henderson Group PLC Acquires 368,908 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 17, 2025 | marketbeat.com

MPM Asset Management LLC Decreases Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 16, 2025 | marketbeat.com

Q2 EPS Forecast for Entrada Therapeutics Reduced by Analyst

May 16, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Dimensional Fund Advisors LP

May 16, 2025 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Issues Earnings Results

May 12, 2025 | marketbeat.com

Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results

May 11, 2025 | finance.yahoo.com

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Entrada Trims Workforce by 20 Percent to Focus on Advancing DMD, Other Candidates

May 2, 2025 | precisionmedicineonline.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Price T Rowe Associates Inc. MD

May 2, 2025 | marketbeat.com

Entrada Therapeutics (TRDA) to Release Quarterly Earnings on Tuesday

May 1, 2025 | marketbeat.com

Entrada Cuts 20% of Workforce, Targeting Research Employees

April 30, 2025 | biospace.com

Entrada lays off 20% of staff weeks after having FDA hold lifted

April 30, 2025 | fiercebiotech.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAP, CMPX, TRDA, and IMMP Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.27 +0.00 (+0.74%)

Closing price 04:00 PM Eastern

Extended Trading

$0.27 0.00 (-0.77%)

As of 04:04 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Compass Therapeutics NASDAQ:CMPX

$2.12 +0.02 (+0.95%)

Closing price 04:00 PM Eastern

Extended Trading

$2.12 +0.00 (+0.24%)

As of 04:04 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Immutep NASDAQ:IMMP

$1.97 +0.04 (+2.07%)

Closing price 04:00 PM Eastern

Extended Trading

$1.99 +0.02 (+0.96%)

As of 04:29 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Entrada Therapeutics NASDAQ:TRDA

$7.90 +0.13 (+1.67%)

Closing price 04:00 PM Eastern

Extended Trading

$7.90 +0.00 (+0.06%)

As of 04:04 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time